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Abstract
 
Selection of immune escape variants impairs the ability of the immune system to sustain an efficient
antiviral response and to control retroviral infections. Like other retroviruses, mouse mammary
tumor virus (MMTV) is not efficiently eliminated by the immune system of susceptible mice. In
contrast, MMTV-infected I/LnJ mice are capable of producing IgG2a virus-neutralizing antibodies,
sustain this response throughout their life, and secrete antibody-coated virions into the milk, thereby
preventing infection of their progeny. Antibodies were produced in response to several MMTV
variants and were cross-reactive to them. Resistance to MMTV infection was recessive and was
dependent on interferon (IFN)-
 
 
 
 production, because I/LnJ mice with targeted deletion of the
INF-
 
 
 
 gene failed to produce any virus-neutralizing antibodies. These findings reveal a novel
mechanism of resistance to retroviral infection that is based on a robust and sustained IFN-
 
 
 
–
dependent humoral immune response.
Key words: IFN-
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Introduction
 
Exogenous mouse mammary tumor virus (MMTV)
 
*
 
 is
transmitted through the milk of infected females to suckling
newborns, where it initially infects cells of the immune
system (1). The MMTV genome encodes a superantigen
(Sag; reference 2) that is presented by MHC class II molecules
expressed on infected B cells and is recognized by TCRs
expressed on cognate T cells (3, 4). Different Sags stimulate
distinct subsets of T cells (each with a particular TCR V
 
 
 
chain), causing them to proliferate and allowing them to
become infected with the virus (5). After the initial pro-
liferation of T cells, steady deletion of the cognate T cells
is observed in all infected mice (6). From the cells of the
immune system, the virus passes to the mammary tissue
and causes mammary carcinomas as a result of insertional
mutagenesis (7).
Three mechanisms of resistance to MMTV infection
in mice have previously been discovered. The first was
mapped to the MHC locus, H2 (8). Inbred mice of 
 
b
 
, 
 
f
 
,
 
q
 
, and 
 
s
 
 H2 haplotypes do not express I-E MHC class II
molecules because of mutations in either the H2-Ea or
H2-Eb gene (9, 10). As I-E H2 molecules are better
suited for Sag presentation, mice with the I-E-negative
H2 haplotypes are relatively resistant to MMTV infection
and MMTV-induced mammary tumors (11–13).
The second mechanism of resistance to MMTV was
found in mice that carry endogenous proviruses, which
encode Sags similar to Sag of exogenous virus. Viral Sags
expressed by endogenous 
 
Mtvs
 
 cause negative selection
of T cells bearing cognate V
 
 
 
 elements in the thymus
and in the periphery (14–16). As a result, mice exposed
to an exogenous MMTV that encodes a Sag with the
same specificity as the endogenous 
 
Mtvs
 
 are resistant to
MMTV infection and do not develop mammary gland
tumors (5, 17).
Previously we have identified a third mechanism of
resistance to MMTV inherited by I/LnJ mice (18). We
showed that resistance to MMTV(C3H)-induced mammary
tumors in mice from this strain is due to impaired mammary
gland infection and is not related to the MHC locus or
presence of endogenous 
 
Mtv
 
s (18). Here we found that
production of avirulent virions by infected I/LnJ cells
underlies the impaired mammary gland infection and
sought to identify the mechanism involved.
 
A. Purdy, L. Case, and M. Duvall contributed equally to this work.
Address correspondence to Dr. T. Golovkina, The Jackson Laboratory,
600 Main St., Bar Harbor, ME 04609. Phone: 207-288-6287; Fax:
207-288-6078; E-mail: tvg@aretha.jax.org
 
*
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; MMTV, mouse
mammary tumor virus; MuLV, murine leukemia virus; Sag, superantigen.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
234
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Materials and Methods
 
Mice.
 
All mice used in this study were bred and maintained at
the animal facility of The Jackson Laboratory. I/LnJ, C3.JK-
 
H2
 
j
 
H2-T18
 
b
 
/Sn (C3.JK), and BALB/cJ mice were purchased from
The Jackson Laboratory. I/LnJ mice were crossed to B6.129S7-
 
Ifng
 
tm1Ts
 
 (19) for 10 repetitive generations, and heterozygous N10
mice were intercrossed to generate I/LnJ mice with targeted mu-
tation of IFN-
 
 
 
 (I/LnJ IFN-
 
 
 
 KO). C3H/HeN MMTV
 
 
 
 mice
infected with the MMTV(C3H) virus variant were purchased
from the National Cancer Institute, Frederick Cancer Research
Facility, Frederick, MD. The MMTV(LA) virus variant (20) was
passed on BALB/cJ mice.
 
Antibodies and Flow Cytometry.
 
Mononuclear peripheral
blood lymphocytes were stained with FITC-coupled monoclonal
antibodies against the V
 
 
 
2, V
 
 
 
6, and V
 
 
 
14 TCR chains (BD
Biosciences). Anti-CD4 antibodies coupled to PE (Life Technol-
ogies) were used in the second dimension. Leukocytes were re-
covered from heparinized blood samples by centrifugation
through a Ficoll/Hypaque cushion. Peripheral blood lympho-
cytes were analyzed using a FACScan™ (Becton Dickinson) flow
cytometer and the CELLQuest™ software program.
 
RNase T
 
1
 
 Protection Assays.
 
RNaseT
 
1
 
 protection assays were
performed as described previously (21), using probes specific for
BALB2, BALBLA, and BALB14 viral transcripts (20). 40 
 
 
 
g of
total RNA isolated from the lactating mammary glands and 5 
 
 
 
g
of RNA isolated from milk were used.
 
Production of Cytokines by Activated T Cells.
 
Anti-CD3 anti-
bodies (5 
 
 
 
g/ml) were attached to 6-well plates for 1.5 h at 37
 
 
 
C
in BBS buffer. Wells were washed with PBS two times. 9 
 
 
 
 10
 
6
 
cells isolated from the lymph nodes pooled from three mice were
added per a well and incubated for 24 h in the CO
 
2
 
 incubator.
RNA isolated from activated cells was subjected to RNase pro-
tection analysis with Riboquant probes using the manufacturer’s
protocol (BD Biosciences). 20 
 
 
 
g of splenic RNA and 5 
 
 
 
g of
lymph node RNA (before and after activation) were loaded on a
6% urea/acrylamide gel.
 
Mammary Gland Tumorigenesis.
 
Mammary gland tumor inci-
dence in MMTV(LA)-infected BALB/cJ and I/LnJ mice was
monitored by weekly palpation of the animals. Tumor-bearing
mice were killed and DNA isolated from a portion of each tumor
was subjected to Southern blot analysis as described previously
(22). All of the tumors contained new MMTV integrants, indicat-
ing that the tumors were caused by the virus (unpublished data).
 
Production of Monoclonal Antibodies against MMTV Virion Pro-
teins.
 
Endogenous 
 
Mtv
 
-free male mice, a gift of Dr. Marrack
(National Jewish Medical and Research Center, Denver, CO;
reference 23), were immunized with 1% Triton X-100-treated
MMTV(LA) virions (100 
 
 
 
g of proteins) in CFA by subcutane-
ous injection in two hind footpads and four locations in the back.
Mice were challenged 3 wk later with the same doses of virion
proteins in IFA. 72 h before fusion mice were challenged with
the same amounts of proteins by intravenous injection. Fusion
was done according to standard protocol. Antibodies were char-
acterized by ELISA and Western blot analysis.
 
ELISA with MMTV Virion Proteins.
 
Either MMTV(C3H)
isolated from the milk of C3H/HeN MMTV
 
 
 
 mice or
MMTV(LA) isolated from the milk of BALB/cLA mice as de-
scribed (20, 23) was resuspended in PBS with 0.2% Triton X-100
and bound to the plate at 0.5 
 
 
 
g/ml in BBS buffer overnight at
4
 
 
 
C. Nonspecific binding was blocked by 1% bovine serum albu-
min for 2 h at 37
 
 
 
C. Secondary antibodies against different mouse
immunoglobulins classes conjugated with alkaline phosphatase
 
(AP) diluted in the ELISA buffer (PBS, 0.05% Tween 20, and
0.1% sodium azide) were used at the second step. Background
obtained with the secondary antibody alone (goat anti–mouse
immunoglobulins coupled to AP) was subtracted. To test for an-
tivirus antibodies in mouse sera, serum samples were diluted in
the ELISA buffer and incubated with virion proteins bound to
plastic before adding the secondary antibodies.
 
Western Blot Analysis.
 
Viral particles were isolated from
BALB/cLA milk. Viral proteins were electrophoresed on 10%
polyacrylamide gels under reducing conditions in the presence of
1% sodium dodecyl sulfate. The proteins were then transferred to
nitrocellulose membranes, treated with different serum samples or
anti-MMTV protein monoclonal antibodies at the first step and
with conjugates coupled to horseradish peroxidase (Upstate Bio-
technology) at the second step, and detected with Western Blot
Detection Reagents (Amersham Biosciences).
 
Immunization.
 
Preimmune sera were collected from 2-mo-old
BALB/cJ and I/LnJ mice, which were then immunized with
MMTV(LA) virion proteins isolated from 100 
 
 
 
l of milk in CFA by
subcutaneous injection in two hind footpads and four locations in the
back. Mice were challenged 3 wk later with the same dose of antigen
in IFA. Serum samples were collected 10 d later and the reactivity of
pre and postimmune serum samples to MMTV(LA) virion proteins
was compared by ELISA. AP-labeled goat anti–mouse immunoglob-
ulin antibodies were used in the second step (Sigma-Aldrich).
 
MMTV Infection.
 
Biologically active MMTV virions were
isolated from the milk of MMTV(LA)-infected BALB/cJ females
as described previously (22, 24). Proteins from virions isolated
from 100 
 
 
 
l of milk were injected intraperitoneally into 3- to
4-wk-old I/LnJ and BALB/cJ females as described previously (24).
 
Virus-Neutralization Assay.
 
The in vitro neutralization proce-
dure was performed at room temperature as published previously
(25). Briefly, purified MMTV(LA) or MMTV(C3H) virions (vir-
ions isolated from 
 
 
 
100 
 
 
 
l of milk in 20 
 
 
 
l of PBS) were incu-
bated with 200 
 
 
 
l of serum from MMTV(LA)-, MMTV(C3H)-
infected or uninfected I/LnJ mice diluted in PBS (1:20) at room
temperature. After 2 h, the resulting 220 
 
 
 
l were injected directly
into the mammary glands of control BALB/cJ mice. For the in
vivo neutralization experiment, newborn BALB/cJ mice suckling
on viremic BALB/cLA females were injected intraperitoneally
with 50 
 
 
 
l of serum from either uninfected or MMTV(LA)-
infected I/LnJ mice (diluted 1/10 in PBS) every other day for 9 d
(5 injections). Mice were bred, and RNA isolated from their lac-
tating mammary glands after the first pregnancy was subjected to
RNase T
 
1
 
 protection analysis with MMTV-specific probes.
 
Results
 
The Mammary Gland Cells of I/LnJ Mice Become Infected
with MMTV(LA), but Viruses Shed into Milk Are Not Infec-
tious.
 
In our previous studies we showed that in I/LnJ mice
exposed to the exogenous MMTV(C3H), infection did not
progress to the mammary glands (18). Another MMTV,
MMTV(LA) originated from BALB/cJ mice, consists of three
different exogenous MMTVs: BALB2, BALBLA, and
BALB14, with V
 
 
 
2-, V
 
 
 
6-, and V
 
 
 
14-specific Sags, respec-
tively (20, 26). These MMTV(LA) viruses are produced at
much higher titers than are MMTV(C3H) viruses (20). To
determine whether infection with MMTV(LA) progresses to
to the mammary glands, I/LnJ mice were fostered by BALB/cJT
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mice infected with MMTV(LA) and frequencies of Sag-
cognate T cells in the periphery were analyzed at 14 wk of
age. Whereas uninfected I/LnJ mice have 9.6 
 
 
 
 0.7% of
CD4
 
 
 
/V
 
 
 
14
 
 
 
 and 6.5 
 
 
 
 0.25% of CD4
 
 
 
/V
 
 
 
2
 
 
 
 T cells (
 
n
 
 
 
 
 
12), MMTV(LA)-infected 14-wk-old I/LnJ mice have
0.89 
 
 
 
 0.6% of CD4
 
 
 
/V
 
 
 
14
 
 
 
 T cells and 0.64 
 
 
 
 0.21% of
CD4
 
 
 
/V
 
 
 
2
 
 
 
 T cells (
 
n
 
 
 
  
 
12). We did not analyze a subset of
CD4
 
 
 
/V
 
 
 
6
 
 
 
 T cells affected by a third virus, MMTV(LA),
present in the mixture, because I/LnJ mice inherit 
 
Mtv7
 
 and
thus, do not have CD4
 
 
 
/V
 
 
 
6
 
 
 
 T cells (18). Infected I/LnJ fe-
males were bred, tested for the presence of virus in their milk,
and monitored for mammary tumors. Mammary glands of all
fostered I/LnJ mice became infected, as they secreted all three
MMTVs into their milk (Fig. 1 A, lanes 1–3). Quantitative
analysis of viral RNA isolated from the milk of infected
mice  ruled out differences in virus titers between infected
BALB/cJ and I/LnJ mice (Fig. 1 D). Thus, in contrast to
MMTV(C3H), infection with a stronger MMTV(LA) virus
variant progressed to the mammary glands of I/LnJ mice.
Although mammary glands of fostered I/LnJ mice became
MMTV infected, they were resistant to mammary tumor de-
velopment. Whereas 80% of MMTV(LA)-infected BALB/cJ
females (16/20) developed mammary tumors by 1 yr of age,
whereas none of 24 I/LnJ females infected with the same vi-
ruses had developed tumors even at 1.5 yr of age.
To determine whether the virus secreted by infected
I/LnJ mice was passed to their offspring, we produced sec-
ond-generation females and tested their milk for virus pres-
ence. Almost all animals either had eliminated the viruses
(Fig. 1 B, lanes 2, 3, 4, 6, and 7) or produced them at sig-
nificantly reduced titers compared with their mothers (Fig.
1 B, lanes 1 and 5). Thus, after only one passage through
I/LnJ mice MMTV(LA) was severely attenuated.
To investigate whether MMTV(LA) produced by in-
fected I/LnJ mice was modified in such a way that it was
no longer infectious in susceptible mice, we examined
MMTV-susceptible BALB/cJ and C3H/HeN mice that
were foster-nursed by the same MMTV(LA)-infected
I/LnJ females. All fostered BALB/cJ and C3H/HeN mice
either did not produce virus or produced virus at much re-
duced titers as determined by RNase T
 
1
 
 analysis with
MMTV(LA)-specific probes (Fig. 1 C, data shown for
BALB/cJ mice only). Thus, although I/LnJ mice became
infected with MMTV(LA), the viruses they produced were
modified such that they lost infectivity.
 
MMTV-infected I/LnJ Mice Produce Antibodies against
MMTV.
 
The results of described experiments suggest
that MMTV proteins required for virus infectivity were
either modified or blocked by anti-virus neutralizing anti-
bodies produced by infected I/LnJ mice. To test this hy-
pothesis, virus was isolated from the milk of MMTV(LA)-
infected I/LnJ and BALB/cJ females and subjected to an
ELISA to test for the presence of immunoglobulins coating
the viral particles. Virus isolated from the milk of infected
I/LnJ females was coated with immunoglobulins of the
IgG2a isotype, while virus isolated from infected BALB/cJ
milk was not (Fig. 2 A, left and right graph).
Figure 1. Virions produced by MMTV(LA)-infected I/LnJ mice are
not infectious. (A) Mammary glands of I/LnJ mice fostered by
MMTV(LA)-infected (BALB/cLA) females become infected and shed
viruses into the milk. I/LnJ females fostered on BALB/cLA milk were
bred, and RNA isolated from their milk was subjected to RNase T1
protection analysis with probes specific for BALB2, BALBLA, and
BALB14. Lanes 1–3: milk RNA from infected I/LnJ mice; lane 4, milk
RNA from uninfected I/LnJ mice. Three different MMTV-infected
I/LnJ mice of 220 tested are shown. (B) Viruses produced by
MMTV(LA)-infected I/LnJ mice cannot infect their offspring. Female
offspring from MMTV(LA)-infected I/LnJ mice were bred, and RNA
isolated from their milk was subjected to RNase T1 protection analysis.
Lanes 1–7: milk RNA from individual infected females fostered by four
different MMTV-infected I/LnJ females. 50 different I/LnJ mice fostered
by 15 distinct MMTV-infected I/LnJ females were tested. (C) Viruses
produced by MMTV(LA)-infected I/LnJ mice are not infectious even in
susceptible BALB/cJ mice. BALB/cJ females were fostered by
MMTV(LA)-infected I/LnJ or BALB/cJ mice. RNA isolated from their
milk after the first pregnancy was subjected to RNase T1 protection
analysis with BALB2, BALBLA, and BALB14-specific probes (BALB2
and BALB14 shown). 1–6, 6 of 15 tested different BALB/cJ females
fostered by 5 distinct MMTV-infected I/LnJ females shown. 7–10,
BALB/cJ mice fostered by BALB/cLA females. Results shown in A, B,
and C were from the same RNase T1 protection experiment using equal
amounts of RNA, and thus, can be compared quantitatively. FLP, full-
length protection. (D) MMTV(LA)-infected BALB/cJ and I/LnJ mice
produce equal amounts of virus into their milk. Top panel, RNA (5
 g) isolated from equal amounts of milk of mice indicated was subjected
to RNaseT1 protection analysis with probes specific for BALB2, BALBLA
and BALB14 sags (only BALBLA is shown). The amount of radioactivity
per viral RNA-specific fragment was quantified using a PhosphorImager.
Bottom panel, the same RNA samples (15  g) were separated on an
agarose gel to verify RNA integrity.T
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Next we sought to determine whether anti-MMTV an-
tibodies were present in the sera of MMTV(LA)-infected
I/LnJ mice. Serum samples were collected from I/LnJ and
BALB/cJ mice that were either infected with MMTV(LA)
through foster nursing or were virus-free. Again we used
ELISA to test for the reactivity of different sera samples to
MMTV(LA) virion proteins bound to the plate. In contrast
to BALB/cLA mice, sera of MMTV(LA)-infected I/LnJ
mice contained antibodies reactive to the MMTV virion
proteins, and these antibodies belonged to the IgG2a iso-
type (Fig. 2 B, top graph).
Unlike MMTV(LA)-infected I/LnJ mice, I/LnJ mice in-
fected with MMTV(C3H) showed impaired mammary
gland infection, whereas hybrid F
 
1
 
 mice obtained from
crosses between susceptible C3H/HeN females and resis-
tant I/LnJ males were susceptible to infection (18). How-
ever, when the F
 
1
 
 females were backcrossed to I/LnJ males,
an N
 
2
 
 generation was produced in which 50% of the fe-
males were mammary gland infected, whereas the other
50% of the females showed impaired mammary gland in-
fection (18). Furthermore, all susceptible N
 
2
 
 females, but
not resistant N
 
2 females, developed mammary tumors (18).
When serum samples from MMTV(C3H)-infected resis-
tant and susceptible N2 females were tested in an ELISA for
their reactivity against MMTV virion proteins it appeared
that all sera from the resistant N2 females contained anti-
MMTV antibodies of the IgG2a isotype (Fig. 2 B, bottom
graph). In contrast, no MMTV(C3H)-infected susceptible
N2 mice showed production of anti-MMTV antibodies
(Fig. 2 B, bottom graph). Thus, resistance to mammary
gland infection and subsequent mammary tumor develop-
ment cosegregated with production of virus-neutralizing
antibodies and are controlled by a single recessive gene.
Such an efficient development of anti-virus antibodies in
I/LnJ mice was unexpected, as these animals were exposed
to MMTV as neonates and, thus, were anticipated to be
tolerant to the viral antigens. Previously we showed that
newly integrated MMTV proviruses were detected in
thymi of I/LnJ mice exposed to the virus as neonates sug-
gesting that they were infected (18). Furthermore, Sag-
cognate T cells were deleted from both CD4  and CD8 
single-positive (SP) thymocytes subsets. The normal per-
centage of V 14  T cells among SP CD4  and CD8  T
cells in thymi of uninfected I/LnJ mice is 11   0.7, n   3
and 4.0   0.4, n   3, respectively. This percentage de-
clined to 6.1   0.9 and 1.2   0.9, n   5, respectively, in
thymi of infected 14-wk-old I/LnJ mice. Thus, although
MMTV infection of the thymus in I/LnJ mice results in
deletion of Sag-reactive T cells, it does not lead to toler-
ance to other viral proteins.
mouse IgG2a-specific immunoglobulins coupled to AP. Bottom graph,
serum samples from MMTV(C3H)-infected resistant and susceptible N2
mice, as well as from MMTV(C3H)-infected I/LnJ, C3H/HeN, and
F1 mice were tested for reactivity against MMTV virion proteins by
ELISA. Anti–mouse IgG2a antibodies coupled to AP were used at the
second step. Sera were diluted 10 3.
Figure 2. MMTV-infected I/LnJ mice produce IgG2a-specific anti-
bodies against MMTV. (A) Viral particles isolated from the milk of I/LnJ
mice fostered by BALB/cLA mothers are coated with antibodies of
the IgG2a isotype. Left graph, virions were purified from the milk of
MMTV(LA)-infected I/LnJ and BALB/cJ mice, bound to plastic, and
analyzed for coating immunoglobulins by ELISA. The reaction was
developed with goat anti–mouse isotype-specific immunoglobulins
coupled to AP. Right graph, purified anti-gp52 mAbs of the IgG1 isotype
were bound to plastic at 3  g/ml followed by incubation with virions
collected from milk of MMTV(LA)-infected BALB/cJ and I/LnJ
mice. ELISA was developed with anti–mouse IgG2a-specific immuno-
globulins coupled to AP. (B) IgG2a-specific antibodies reactive against
MMTV virion proteins are present in the sera of MMTV-infected I/LnJ
mice and resistant N2 mice. Top graph, the ELISA was performed
with MMTV(LA) virion proteins isolated from 8-wk-old BALB/
cLA mice and serum samples from age-matched uninfected or
MMTV(LA)-infected I/LnJ and BALB/cJ mice and developed with
either goat anti–mouse polyvalent immunoglobulins or goat anti-T
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Antibodies Produced by Infected I/LnJ Mice React with Major
Virion Proteins and Are Capable of Neutralizing MMTV. To
determine which viral proteins are recognized by anti-
MMTV antibodies, lysates of MMTV(LA) viral particles
purified from the milk of BALB/cLA females were sepa-
rated by denaturing PAGE, transferred to nitrocellulose,
and incubated with sera from either infected or uninfected
I/LnJ mice. The blots were then developed with conju-
gated secondary antibodies against either IgG2a or IgG1
mouse immunoglobulins. There are three major proteins
within the MMTV virion: gp52, the surface (SU) protein
product of the env gene; gp36, the transmembrane (TM)
product of the env gene; and p27, the product of the gag
gene. A pool of sera from three uninfected I/LnJ mice
showed no reactivity against any of these MMTV proteins
(Fig. 3 A). In contrast, all six MMTV(LA) infected I/LnJ
mice tested produced anti-gp52 and anti-gp36 antibodies as
well as antibodies against p27 (Fig. 3 A). Most of the reac-
tive antibodies were of the IgG2a isotype (Fig. 3 A). Thus,
MMTV-infected I/LnJ mice are capable of making anti-
bodies against internal and surface viral proteins.
Antibodies produced by MMTV-infected I/LnJ mice
were tested for their ability to neutralizing virus in
two  types of assays. First, sera from 3- to 4-mo-old
MMTV(LA)-infected I/LnJ and BALB/cJ mice were used
in an in vitro neutralization assay. Sera from age-matched
uninfected I/LnJ and BALB/cJ mice were used as controls.
Purified MMTV(LA) virions incubated with different sera
were injected directly into the mammary glands of previ-
ously uninfected BALB/cJ mice. All successfully infected
mice show deletion of Sag-cognate T cells (6, 27). The de-
letion of Sag-cognate T cells measured 8 wk after infection
was used as indicator of virus infectivity. Uninfected con-
trol BALB/cJ mice have 9.2   0.8% of peripheral
CD4 V 14  T cells, n   10. BALB/cJ mice injected with
virus preincubated with infected BALB/cJ serum, unin-
fected BALB/cJ serum, or uninfected I/LnJ serum became
infected with MMTV, showing a diminution in the per-
centage of CD4 V 14  to 2.4   0.6%, n   5, to 2.1  
0.7%, n   5, and to 2.8   1.2, n   5, respectively. Only
BALB/cJ mice injected with MMTV virions preincubated
with MMTV(LA)-infected I/LnJ serum did not show dele-
tion of CD4 V 14  (10.5   0.4%, n   5), suggesting that
they were virus-free. Furthermore, the same BALB/cJ
mice did not show mammary gland infection as determined
by RNase T1 protection analysis (unpublished data). We
have  also performed experiments with MMTV(C3H)
virions preincubated with MMTV(LA)-infected I/LnJ
sera and with MMTV(LA) virions preincubated with
MMTV(C3H)-infected I/LnJ sera and obtained similar re-
sults (unpublished data). Thus, MMTV pretreatment with
serum from infected I/LnJ mice in vitro results in virus
neutralization and block of infection.
Second, in order to determine whether antibodies pro-
duced by infected I/LnJ mice were capable of neutralizing
virus in vivo, newborn mice infected with MMTV were
used. Two groups of newborn BALB/cJ mice suckling on
viremic mothers were injected with sera from MMTV-
infected or uninfected I/LnJ mice. Pubescent mice were
bred and RNA isolated from their lactating mammary
glands was subjected to an MMTV-specific RNase T1 pro-
tection assay (Fig. 3 B). Only mice injected with sera from
infected I/LnJ mice were protected from MMTV, as no
MMTV(LA)-specific transcripts were detected in their
mammary glands. Thus, antibody-containing sera of
MMTV(LA)-infected I/LnJ mice neutralize virus infectiv-
ity in susceptible mice in vitro and in vivo.
The Kinetics of Anti-MMTV Antibody Production and a
Class Switch to IgG2a in Naturally Infected I/LnJ and BALB/cJ
Mice. By 8 wk of age naturally infected I/LnJ mice
produce virus-specific antibodies of the IgG2a isotype
(Fig. 2 B). To determine when this antibody response is
Figure 3. Antibodies produced by MMTV-infected I/LnJ mice recognize
major virion proteins and neutralize the virus in vivo. (A) Antibodies
produced by MMTV-infected I/LnJ mice recognize major virion proteins.
Western blot analysis of MMTV virion proteins with sera of
MMTV(LA)-infected I/LnJ mice. MMTV(LA) purified from the milk of
BALB/cLA females was run on a 10% denaturing acrylamide gel, blotted
to nitrocellulose, and incubated with mouse monoclonal antibodies
against gp52 (a-gp52), p27 (a-p27), gp36 (a-gp36), or sera (10 2 dilution)
from infected I/LnJ mice (I/LnJ MMTV ) or uninfected I/LnJ mice
(I/LnJ).  Blots were developed with anti–mouse polyclonal, or anti–
mouse IgG2a-specific or IgG1-specific antibodies coupled to horseradish
peroxidase. 1–6, individual mice of 30 tested. (B) Sera from MMTV-
infected I/LnJ mice protect susceptible mice from MMTV infection.
BALB/cJ mice fostered by viremic BALB/cLA females were injected as
newborns with sera from uninfected or infected I/LnJ mice. RNA
isolated from lactating mammary glands of these animals was screened
for viral transcripts in an MMTV-specific RNase T1 protection analysis
(BALB2 and BALB14 probes shown).T
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initiated and whether it is unique to I/LnJ mice, suscepti-
ble BALB/cJ mice and resistant I/LnJ mice were fostered
on viremic BALB/cJ females and presence of antibodies
against MMTV in their sera was analyzed by ELISA at
different time point. Two different secondary antibodies
were used to detect antibodies present in the sera by
ELISA: anti–mouse Ig nonisotype specific and IgG2a-spe-
cific antibodies (Fig. 4). These experiments revealed that
the initial production of anti-MMTV antibodies could be
detected in both infected I/LnJ and BALB/cJ mice from
3 to 6 wk after birth. However, antibodies were no
longer observed in BALB/cJ mice after they reached 6 to
7 wk of age. In addition, the temporal production of anti-
MMTV antibodies in BALB/cJ mice did not include a
specific increase in antibodies of the IgG2a isotype, as no
such antibodies were detected in BALB/cJ sera. Thus,
susceptible BALB/cJ mice were incapable of mounting a
long-lasting antibody response against virus and did not
class-switch to the IgG2a isotype. In contrast, in I/LnJ
mice, after a wave of poly-isotypic early response, a steady
and increasing production of anti-MMTV antibodies of
the IgG2a isotype began at  6 wk of age (Fig. 4).
INF-  Is Required for Anti-virus Antibody Production in
I/LnJ Mice. Neonatally MMTV-infected I/LnJ mice
produce  anti-virus neutralizing antibodies of the IgG2a
isotype and sustain this production throughout their life-
time. Class switching to the IgG2a isotype is induced
primarily by IFN-  (28). IFN-  is a pleiotropic cytokine
that plays a central role in promoting innate and adaptive
mechanisms of host defense (29).
To demonstrate that IFN-  is involved in resistance of
I/LnJ mice to retroviral infection, mice with targeted muta-
tion if IFN-  (30) were backcrossed to I/LnJ mice for 10
generations. To investigate whether IFN-  KO I/LnJ mice
are susceptible to MMTV infection, they were fostered by
viremic females along with their heterozygous littermates,
and kinetics of antivirus antibody production was studied.
All animals became MMTV infected since they demon-
strated deletion of peripheral Sag-cognate CD4 /V 14  T
cells. MMTV(LA)-infected 8-wk-old IFN-  KO/KO,
KO/ , and  /  mice had 0.8   0.3% (n   5), 0.87  
0.4% (n   8), and 0.8   0.5% (n   4) of CD4 /V 14  T
cells, respectively, whereas uninfected mice of the same geno-
types had 9.5   07% (n   5), 9.3   0.5% (n   5), and 9.7  
0.2% (n   6) of CD4 /V 14  T cells, respectively. Further-
more, all animals contained newly integrated MMTV provi-
ruses within the lymphoid system and the virus load did not
differ between mice of three different genotypes (Fig. 5 A).
These data suggest that IFN-  is not required for MMTV in-
fection and its absence does not increase the virus load.
To determine whether IFN-  was necessary for anti-
MMTV antibodies production, infected IFN- –deficient
and IFN- –sufficient I/LnJ mice were bled and their sera
were tested for reactivity against MMTV in ELISA. None
of MMTV-infected IFN- –deficient mice produced anti-
MMTV antibodies, whereas initial polyvalent response fol-
lowed by the class switch to IgG2a isotype was apparent in
IFN- –sufficient mice (Fig. 5 B).
To investigate whether failure to produce anti-virus
antibodies by IFN- –deficient mice results in successful
Figure 4. Kinetics of anti-MMTV antibody appearance
in neonatally infected I/LnJ and BALB/cJ mice. Mice of
each strain were bled weekly from 3 to 8 wk of age, and
the presence of antibodies against MMTV virion proteins
in their sera was detected by an ELISA (shown for three
individual mice). A 2.5   10 2 dilution of sera was used
in this experiment. Average readings obtained with sera
from age-matched uninfected mice were subtracted. 1–3,
individual mice at 8 wk of age. Bottom right graph, the
same #1–3 I/LnJ mice at 30 wk. Importantly, anti-
MMTV antibody production steadily increased in infected
I/LnJ mice.T
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virus transmission, we fostered susceptible BALB/cJ mice
by MMTV-infected IFN- –deficient and IFN- –sufficient
I/LnJ mice and analyzed the frequencies of Sag-cognate T
cells in the periphery of 8-wk-old mice (Fig. 5 C). All
BALB/cJ mice fostered on IFN- –sufficient I/LnJ mice
did not become MMTV infected and had normal frequen-
cies of Sag-cognate T cells. In contrast, BALB/cJ mice fos-
tered by IFN- –deficient I/LnJ mice became MMTV in-
fected, as they showed deletion of Sag-cognate T cells (Fig.
5 C). Importantly, the steady state level of IFN-  in the
sera of I/LnJ mice was no different from that in the sera of
C3H/HeN and BALB/cJ mice and was below the detect-
able 30 pg/ml. Similarly, the level of IFN-  produced by T
cells in response to anti-CD3 antibodies was similar in sus-
ceptible and resistant mice (Fig. 6). Thus, antiretroviral hu-
moral immune response in I/LnJ mice is determined by the
IFN-  produced specifically in response to viral infection.
Antivirus Antibodies of the IgG2a Isotype Are a Specialized
Response to Retroviral Infection. MMTV infection in I/LnJ
mice results in production of antivirus antibodies of the
IgG2a isotype (Fig. 2). It is possible that all antibody re-
sponses in I/LnJ mice were skewed toward the IgG2a
isotype or it is also possible that this resulted from the
activation of a specific pathway in response to retroviral
infection. Immunization of I/LnJ mice with ovalbumin re-
sulted in production of antibodies of multiple isotypes and
did not differ from a response in BALB/cJ mice (unpub-
lished data). Moreover, when both I/LnJ and control
BALB/cJ mice were immunized with MMTV virion pro-
Figure 5. IFN-  is required for antivirus antibody production in I/LnJ
mice. (A) IFN-  is not required for initial infection and its absence does not
lead to an increase in virus load. PCR was performed with BALB14 LTR-
specific primers under semiquantitative conditions (reference 20) with 0.1
mg of DNA isolated from spleens of infected IFN- –sufficient or IFN- –
deficient I/LnJ mice nursed by BALB/cLA females. All mice analyzed
were 3-mo-old. I/LnJ, splenic DNA from an uninfected I/LnJ mouse.
MMTV, PCR product of predicted 590 bp. Densitometry was done on
the Nighthawk gel documentation system (PDI). (B) MMTV-infected
IFN- –deficient I/LnJ mice are not capable of making anti-MMTV anti-
bodies. Serum samples from MMTV(LA)-infected IFN-  KO/KO, KO/ ,
and  /  (unpublished data) I/LnJ mice were tested for reactivity against
MMTV virion proteins by ELISA at different time points. Anti–mouse
IgG2a antibodies or anti-mouse polyvalent antibodies coupled to AP
were used at the second step. Sera were diluted 2.5   10 2. IFN-   / 
mice showed the same phenotype as IFN-  KO/  mice (unpublished
data). (C) IFN-  deficiency results in production of infectious virions by
I/LnJ mice. BALB/cJ females were fostered by MMTV(LA)-infected
IFN- –deficient or IFN- –sufficient I/LnJ mice. Mice were bled at 8 wk of
age and their peripheral blood lymphocytes were analyzed for the frequencies
of Sag-cognate CD4  T cells (V 2  and V 14 ). Three IFN-  KO/KO,
three IFN-  KO/ , and two IFN-   /  MMTV(LA)-infected I/LnJ
foster mothers were used for these experiments.
Figure 6. Resistant I/LnJ mice and susceptible C3H/HeN mice do not
differ in IFN-  levels triggered by conventional stimuli. RNA isolated
from anti-CD3 activated age- and sex-matched I/LnJ (pool of three
mice) and C3H/HeN (pool of three mice) splenocytes was subjected to
RNase protection analysis with Riboquant probes. This experiment was
repeated two more times with the same results. SP, spleen; LN, peripheral
lymph nodes; L32 and GAPDH, housekeeping genes.T
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teins in CFA their responses were remarkably similar (Fig.
7). Neither I/LnJ mice nor BALB/cJ mice immunized
with virion proteins in CFA show a bias in production of
anti-virus antibodies toward the IgG2a isotype (Fig. 7). As
a control, a group of I/LnJ mice and a group of BALB/cJ
mice were injected intraperitoneally with biologically ac-
tive MMTV(LA). While MMTV(LA)-infected I/LnJ mice
produced antivirus antibodies of only the IgG2a isotype,
MMTV-infected BALB/cJ mice failed to produce antivirus
antibodies (Fig. 7). Thus, the immune response in I/LnJ
mice is not skewed in general toward the IgG2a isotype.
After immunization with MMTV proteins in CFA, even
susceptible BALB/cJ mice were capable of producing vi-
rus-neutralizing antibodies, because MMTV virions prein-
cubated with sera from immunized BALB/cJ mice com-
pletely neutralized the virus in in vitro experiment.
Uninfected control BALB/cJ mice had 9.2   0.8%, n   10
of CD4 V 14  T cells. BALB/cJ mice injected with
MMTV virions preincubated with sera from either I/LnJ
or BALB/cJ mice immunized with MMTV(LA) virion pro-
teins did not show deletion of CD4 V 14  T cells (9.6  
0.37% for 5 I/LnJ sera and 9.6   0.7 for 5 BALB/cJ
sera), suggesting that they were virus-free. In contrast, sera
from MMTV(LA)-infected BALB/cJ mice did not neutral-
ize the virus (2.79   1% of CD4 V 14  T cells, n   5).
As expected, control sera from infected I/LnJ mice com-
pletely blocked infection (9.8   0.4% of CD4 /V 14  T
cells, n   5). Thus, immunization with MMTV virion pro-
teins in adjuvant, but not a natural infection, stimulates
production of virus-neutralizing antibodies in susceptible
BALB/cJ mice. In contrast, resistant I/LnJ mice have a
unique ability to produce neutralizing antibodies upon in-
fection without exogenous adjuvant.
Discussion
Humoral immune responses play an important role in an-
tiviral defense. Antiviral antibodies prevent the spread of viral
infections through two main mechanisms: (a) block of inter-
actions of viral surface proteins (Env) with their receptors;
(b) facilitation of virus uptake into phagocytic cells through
interaction with the Fc receptors or through the comple-
ment pathway. Although for many viral infections antibody
production is a key to clearance (31), retroviruses such as
HIV are able to escape humoral immune responses despite
the fact that anti-HIV antibodies are being produced (32).
Retroviral infections persist and involve rapid mutations of
genes that encode antigenic proteins, leading to selection of
immune escape variants. In order for a humoral immune re-
sponse against a retrovirus to be capable of blocking virus
transmission, it must be robust and sustained. I/LnJ mice are
unique in meeting these requirements: they efficiently gen-
erate anti-MMTV neutralizing antibodies, they are able to
sustain this response throughout their lifespan (Fig. 4) and
they produce antibodies against multiple viral proteins that
cross-react with different MMTV variants (Fig. 3).
Our interest was drawn to I/LnJ mice because of their
remarkable resistance to MMTV-induced mammary tu-
mors (11, 18) and we searched for the mechanism underly-
ing this resistance. We found that MMTV-infected I/LnJ
mice produced antibodies against the virus that were able
to (a) neutralize MMTV in vitro; (b) abort MMTV infec-
tion when injected in vivo (Fig. 3 C); and (c) coat virions
secreted into milk (Fig. 2 A), thereby preventing further vi-
rus transmission. Antibodies were produced in response to
four MMTV variants: MMTV(C3H), BALB2, BALB14,
and BALBLA, and were cross-reactive to them. It is possi-
ble that the antibodies recognize protein determinants that
viruses cannot change without losing infectivity.
The unique features of the I/LnJ response to MMTV
are that such a response is elicited and maintained. We
(Fig. 4) and others (33–35) have found that mice suscep-
tible to MMTV infection and MMTV-induced tumors
are capable of producing anti-MMTV antibodies. How-
ever, the kinetics of this response in I/LnJ is distinct
from that in susceptible mice. The initial production of
anti-MMTV antibodies in infected BALB/cJ mice
started at 3 wk after birth and was terminated at 6 to 7
wk (Fig. 4). In addition, this transient production of
anti-MMTV antibodies in BALB/cJ mice did not in-
clude a specific increase in antibodies of the IgG2a iso-
type. In contrast, I/LnJ mice demonstrated a steadily in-
creasing response that was detectable at 4 wk after birth
and class switched to the IgG2a isotype at  7 wk (Fig.
4). This means that both MMTV-susceptible and
MMTV-resistant mice did not recognize retroviral anti-
gens as “self” when they were infected as newborns (Fig.
Figure 7. Infection with MMTV is required to induce an IgG2a-biased
virus-neutralizing immune response. Adult I/LnJ and BALB/cJ mice
were immunized with MMTV(LA) virion proteins and their pre- and
postimmune sera were tested 30 d later in an ELISA for reactivity against
virion proteins. Another group of age-matched and sex-matched mice
was injected intraperitoneally with the same amount of biologically active
MMTV(LA), and their sera were tested 30 d later for anti-MMTV anti-
bodies. All sera were used at 10 2 dilution. Goat anti–mouse IgG2a- and
IgG1-specific antibodies were used at the second step. Data from individual
mice are shown. Additional mice were analyzed by Western blot.
Whereas 7/7 and 2/7 infected adult I/LnJ mice showed production of
MMTV-specific antibodies of the IgG2a and IgG1 isotype, respectively,
all immunized I/LnJ mice produced anti-MMTV antibodies of both the
IgG2a and IgG1 isotype. In contrast, 0/10 infected adult BALB/cJ
mice showed production of any anti-MMTV antibodies, while 5/5 of
immunized BALB/cJ mice produced anti-MMTV antibodies of both
the IgG2a and IgG1 isotype.T
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4). However, over time the immune system of suscepti-
ble BALB/cJ mice became tolerant to these viral anti-
gens and no longer recognizes them as foreign (Fig. 4).
In contrast, in I/LnJ mice, antibody production is sus-
tained throughout their life (Fig. 4). From these data we
concluded that the immune system of I/LnJ mice is al-
ways aware of retroviral infection.
Infection per se must be a key to production of anti-
virus antibodies of exclusively IgG2a isotype in I/LnJ mice,
as the production of antibodies of different isotypes against
viral proteins were seen in both susceptible and resistant
mice when viral proteins were introduced with an adjuvant
(Fig. 7). Pathogens (including viruses) are capable of acti-
vating APCs through their pathogen-associated molecular
patterns (PAMPs), which are recognized by innate immune
pattern recognition receptors (PRR; references 36 and 37).
Unique molecular features of viruses, such as double-
stranded (ds) RNA, can serve as PAMP. Indeed, dsRNA
was recently found to be recognized by Toll-like receptor
(TLR)3 (38). Recently TLRs and their adaptor proteins
were linked to IFN pathways and in some cases were actu-
ally induced by IFNs during viral infection (39, 40). In the
case of retroviruses it remains unclear what receptors are
activated, but I/LnJ mice clearly demonstrate that infection
leads to an efficient immune response, implying that
MMTV may activate innate immunity.
I/LnJ mice with targeted mutation of IFN-  were unable
to produce any antibodies against the virus (Fig. 5), implicat-
ing IFN-  in the mechanism of resistance inherited by I/LnJ
mice. Although we found no evidence of increased IFN- 
production by activated I/LnJ T cells or increased IFN- 
background levels in the sera of I/LnJ mice (Fig. 6), it is
plausible that increased IFN-  production might occur in
response to stimuli other than T cell receptor ligation or by
other cell types.
IFN-  is mostly produced by NK cells and certain sub-
populations of T cells and activates expression of IFN- –
responsive genes whose products are engaged in the immune
response (41). Other cell types, however, may be also in-
volved in IFN-  production. Our preliminary data showed
that cells of I/LnJ bone marrow origin are capable of con-
veying the ability to produce anti-MMTV neutralizing anti-
bodies by susceptible mice (unpublished data).
The precise details of the resistance mechanism in I/LnJ
mice are yet to be elucidated. Previously we showed that it is
controlled by a single gene, virus infectivity controller or Vic
(18). Our preliminary mapping data position the gene on
Chromosome 17 (not MHC-linked; unpublished data). Two
alleles of the Vic gene of I/LnJ origin are required for antibody
production, whereas one allele of the gene from susceptible
mice is needed to suppress antibody production. The fact that
resistance is recessive suggests that some type of negative regu-
latory activity is abolished or reduced in I/LnJ mice, allowing
these mice to sustain an immune response against retrovirus.
For example, it is possible that a negative feed back regulation
of IFN-  signaling is affected, leading to normal (not exces-
sive) but sustained IFN-  production. One well-known nega-
tive regulator of IFN-  is the cytokine inducible SH2-con-
taining protein 1 (CISH1), which is induced in response to
IFN-  stimulation (42). However, we did not find any differ-
ences between resistant I/LnJ mice and susceptible mice in the
coding sequences of Cish1 gene or in up-regulation of Cish1
mRNA in response to IFN-  (unpublished data). Initial rec-
ognition of MMTV as “nonself” takes place in other strains as
well as in I/LnJ mice, but only I/LnJ mice continue to recog-
nize MMTV antigens as “nonself.” Thus, susceptible mice be-
come tolerant to MMTV, while resistant I/LnJ mice maintain
antiviral immune response, a property for which IFN-  may
be also responsible. One would anticipate that these mice must
be more prone to autoimmunity than other strains. This,
however, is not the case, as no reports of autoimmunity in
I/LnJ mice have been published, and we have not made any
such observations in our colony. Moreover, I/LnJ mice as
well as other mouse strains have endogenous Mtvs (18), but
only I/LnJ mice produce anti-viral antibodies when infected
with exogenous MMTV. Thus, the mechanism that allows
I/LnJ mice to sustain the antiviral response is absolutely de-
pendent on infection with retrovirus.
Another known example of resistance to retroviral infec-
tion is resistance to Friend murine leukemia virus (MuLV)
conferred by a dominant allele of the Rfv3 gene. The pro-
duction of virus-neutralizing antibodies of the IgG2a isotype
against Friend MuLV underlies this resistance and results in
complete virus clearance (43). Although function of the Rfv3
gene also remains unknown, the mechanism of action of its
encoded product is clearly different from that of the Vic
gene. The resistant allele of the Rfv3 gene is dominant, since
only one copy is required for the production of anti-F-
MuLV neutralizing antibodies (43). In addition, the Rfv3
gene was mapped to Chromosome 15 (44, 45), whereas the
Vic gene has been mapped to Chromosome 17.
Thus, we have discovered a novel mechanism of resis-
tance to retroviral infection that results in an efficient antivi-
rus antibody response and blocks virus transmission. Both
neutralizing anti-virus antibodies and cytotoxic lymphocytes
directed against viral proteins can be detected in humans in-
fected with HIV (46). However, the level at which they
control HIV infection is insufficient to prevent the disease
from progressing, and virus variants that escape immune rec-
ognition are often found in HIV-infected individuals (47). If
we knew a way to make the immune response against HIV
and other human retroviruses robust and sustained, we
would be better able to treat diseases caused by them.
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